Liminatus Pharma, Inc.
LIMN
$0.14
$0.013.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.12M | -8.17M | -1.82M | -214.00K | -327.50K |
| Total Depreciation and Amortization | 500.00 | 500.00 | 500.00 | 700.00 | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.20K | 7.39M | 1.10M | -1.27M | -- |
| Change in Net Operating Assets | -896.30K | 389.60K | 119.10K | -7.49M | 168.10K |
| Cash from Operations | -2.02M | -386.80K | -600.60K | -8.98M | -159.40K |
| Capital Expenditure | -- | 0.00 | -13.10K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.00 | 0.00 | -775.00K | -575.00K |
| Cash from Investing | -- | 0.00 | -13.10K | -775.00K | -575.00K |
| Total Debt Issued | -- | 0.00 | 0.00 | 4.34M | 713.00K |
| Total Debt Repaid | -- | 0.00 | 0.00 | -1.30M | -- |
| Issuance of Common Stock | 3.59M | 0.00 | 0.00 | 10.56M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | -2.56M | -- |
| Cash from Financing | 3.59M | 0.00 | 0.00 | 11.03M | 713.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.57M | -386.80K | -613.70K | 1.28M | -21.40K |